Bone Biologics Corp (BBLGW) Net Income towards Common Stockholders (2010 - 2025)

Bone Biologics (BBLGW) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$684643.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders rose 55.01% year-over-year to -$684643.0; the TTM figure through Dec 2025 stood at -$3.1 million (up 57.8% YoY), while the FY2025 annual figure was -$3.1 million, up 57.56% from the prior year.
• Net Income towards Common Stockholders fell to -$684643.0 in Q4 2025 per BBLGW's latest filing, from -$666737.0 in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$176137.0 in Q4 2021 and bottomed at -$21.6 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$2.3 million across 5 years, with a median of -$848899.5 in 2024.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 12185.38% — and 2023, when it jumped 92.84%.
• Bone Biologics' Net Income towards Common Stockholders stood at -$176137.0 in 2021, then sank by 12185.38% to -$21.6 million in 2022, then surged by 92.84% to -$1.5 million in 2023, then grew by 1.82% to -$1.5 million in 2024, then soared by 55.01% to -$684643.0 in 2025.
• Business Quant data shows BBLGW's Net Income towards Common Stockholders at -$684643.0 in Q4 2025, -$666737.0 in Q3 2025, and -$741421.0 in Q2 2025.